Host-directed immunotherapy of viral and bacterial infections: past, present and future

RS Wallis, A O'Garra, A Sher, A Wack - Nature Reviews Immunology, 2023 - nature.com
The advent of COVID-19 and the persistent threat of infectious diseases such as
tuberculosis, malaria, influenza and HIV/AIDS remind us of the marked impact that infections …

Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies

S Tiberi, N du Plessis, G Walzl, MJ Vjecha… - The Lancet Infectious …, 2018 - thelancet.com
Tuberculosis remains the world's leading cause of death from an infectious disease,
responsible for an estimated 1 674 000 deaths annually. WHO estimated 600 000 cases of …

Disease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients

AC Aschenbrenner, M Mouktaroudi, B Krämer… - Genome medicine, 2021 - Springer
Abstract Background The SARS-CoV-2 pandemic is currently leading to increasing numbers
of COVID-19 patients all over the world. Clinical presentations range from asymptomatic …

Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives

SM Gygli, S Borrell, A Trauner… - FEMS microbiology …, 2017 - academic.oup.com
Antibiotic-resistant Mycobacterium tuberculosis strains are threatening progress in
containing the global tuberculosis epidemic. Mycobacterium tuberculosis is intrinsically …

The Macrophage: A Disputed Fortress in the Battle against Mycobacterium tuberculosis

CJ Queval, R Brosch, R Simeone - Frontiers in microbiology, 2017 - frontiersin.org
Mycobacterium tuberculosis (Mtb), the etiological agent of human tuberculosis (TB), has
plagued humans for thousands of years. TB still remains a major public health problem in …

Host-directed therapies for infectious diseases: current status, recent progress, and future prospects

A Zumla, M Rao, RS Wallis, SHE Kaufmann… - The Lancet Infectious …, 2016 - thelancet.com
Despite extensive global efforts in the fight against killer infectious diseases, they still cause
one in four deaths worldwide and are important causes of long-term functional disability …

[HTML][HTML] Human tuberculosis and Mycobacterium tuberculosis complex: A review on genetic diversity, pathogenesis and omics approaches in host biomarkers …

RD Kanabalan, LJ Lee, TY Lee, PP Chong… - Microbiological …, 2021 - Elsevier
Mycobacterium tuberculosis complex (MTBC) refers to a group of mycobacteria
encompassing nine members of closely related species that causes tuberculosis in animals …

Tuberculosis—advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers

RS Wallis, M Maeurer, P Mwaba, J Chakaya… - The Lancet infectious …, 2016 - thelancet.com
Tuberculosis is the leading infectious cause of death worldwide, with 9· 6 million cases and
1· 5 million deaths reported in 2014. WHO estimates 480 000 cases of these were multidrug …

Molecular determinants in phagocyte-bacteria interactions

SHE Kaufmann, A Dorhoi - Immunity, 2016 - cell.com
Phagocytes are crucial for host defense against bacterial pathogens. As first demonstrated
by Metchnikoff, neutrophils and mononuclear phagocytes share the capacity to engulf, kill …

Host directed therapies for tuberculosis: futures strategies for an ancient disease

I Palucci, G Delogu - Chemotherapy, 2018 - karger.com
The emergence and spread of drug-resistant strains of Mycobacterium tuberculosis is
worsening the global threat of tuberculosis (TB). There is a need and urgency for the …